EGFR ACTIVATING MUTATIONS IN NSCLC: IMPORTANCE OF ROUTINE TESTING

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author TAKAHASHI, Tiago K. FMUSP-HC
SOARES, Ibere C. FMUSP-HC
MARINI, Andrea M. FMUSP-HC
MAK, Milena P. FMUSP-HC
TEIXEIRA, Carlos H.
ROITBERG, Felipe S. R. FMUSP-HC
TAKAGAKI, Teresa Y. FMUSP-HC
MARTINS, Renata E. FMUSP-HC
MESQUITA, Cristiane FMUSP-HC
HOFF, Paulo M. G. FMUSP-HC
CASTRO JR., Gilberto FMUSP-HC
dc.date.issued 2012
dc.identifier.citation JOURNAL OF THORACIC ONCOLOGY, v.7, n.7, p.S129-S129, 2012
dc.identifier.issn 1556-0864
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/2827
dc.description.abstract Background: EGFR activating mutations in NSCLC confer better prognosis and are also predictive of response to both chemotherapy and EGFR-tyrosine kinase inhibitors. Therefore, EGFR genotyping in NSCLC patients (pts) is very helpful in treatment decision. Here we report the first 25 pts whose tumors samples were tested for EGFR activating mutations in our Institution. Methods: It is an observational study on all consecutively tested NSCLC samples from pts treated at ICESP. Briefly, all samples were formalin-fixed and paraffin-embedded. Tumor areas were selected and macrodissected, followed by whole DNA extraction and amplification by PCR. DNA sequencing (exons 18, 19, 20 and 21) was performed by Sanger´s methodology. Frequencies were compared by Fisher´s exact test. Results and Conclusion: Results: 25 tumor samples were tested from Aug/2011 up to now: 20 pts were caucasian, 13 were male, 14 ex-smoker, 10 never smoker; 15 pts ECOG-PS 0-1 and 5 PS 2. Regarding histologic subtype, 22 were classified as adenocarcinoma and 2 SCC. Staging: 3 IIIA, 2 IIIB and 20 IV. Activating mutations were detected in 6 pts (24%): 4 in exon 19 (del 19), 1 in exon 21 (L858R) and in 1 pt two mutations were found (T790M and L858R). The frequency of these activating mutations was not related to gender (p=0.378), race (p=0.540) or smoking habits (p=0.350). In a short follow-up of 6 mo., no deaths occurred in pts whose samples were positive for activating mutations. Conclusions: In this very selected population, the frequency of EGFR activating mutations was 24%, with no correlation with gender, race or smoking habits. This reinforces the importance of testing EGFR activating mutations in all pts with lung adenocarcinoma. Disclosure: No significant relationships.
dc.language.iso eng
dc.publisher LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof Journal of Thoracic Oncology
dc.rights restrictedAccess
dc.title EGFR ACTIVATING MUTATIONS IN NSCLC: IMPORTANCE OF ROUTINE TESTING
dc.type conferenceObject
dc.rights.holder Copyright LIPPINCOTT WILLIAMS & WILKINS
dc.description.conferencedate JUL 25-27, 2012
dc.description.conferencelocal Rio de Janeiro, BRAZIL
dc.description.conferencename 5th Latin American Conference on Lung Cancer (LALCA 2012)
dc.description.group LIM/24
dc.description.group LIM/14
dc.type.category meeting abstract
dc.type.version publishedVersion
hcfmusp.author TAKAHASHI, Tiago K.:HC:ICESP
hcfmusp.author SOARES, Ibere C.:FM:
hcfmusp.author MARINI, Andrea M.:HC:ICHC
hcfmusp.author MAK, Milena P.:HC:ICESP
hcfmusp.author ROITBERG, Felipe S. R.:HC:ICESP
hcfmusp.author TAKAGAKI, Teresa Y.:HC:ICHC
hcfmusp.author MARTINS, Renata E.:FM:
hcfmusp.author MESQUITA, Cristiane:HC:ICESP
hcfmusp.author HOFF, Paulo M. G.:FM:MDR
hcfmusp.author CASTRO JR., Gilberto:HC:ICESP
hcfmusp.author.external · TEIXEIRA, Carlos H.:Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000306458700056
hcfmusp.publisher.city PHILADELPHIA
hcfmusp.publisher.country USA
dc.description.index MEDLINE
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics